{"schema_version":"secwatch.filing_event.v1","accession":"0000897101-24-000069","form_type":"8-K","ticker":"ELMD","cik":"0001488917","company_name":"Electromed, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.310492+00:00","generated_at":"2026-06-06T03:20:33.600926+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Electromed Q2 FY2024 revenue record $13.7M (+17% YoY), EPS $0.19 vs $0.11","bullets":["Net revenue increased 17% to record $13.7M; direct homecare revenue up 18% to $12.7M.","Gross margins improved to 77% from 74%; operating income record $2.263M (16.5% of revenue).","Diluted EPS $0.19 vs $0.11; net income record $1.674M.","Cash $10.4M, no debt; annualized homecare revenue per rep $1,007,000 above target range.","Field sales force totaled 58, with 49 direct sales representatives."],"urls":{"canonical":"https://secwatch.observer/filing/0000897101-24-000069","json":"https://secwatch.observer/filing/0000897101-24-000069.json","markdown":"https://secwatch.observer/filing/0000897101-24-000069.md","text":"https://secwatch.observer/filing/0000897101-24-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488917/000089710124000069/0000897101-24-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488917/000089710124000069/elmd240161_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:20:33.600926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddbded098140f0d24b8adcbe789c26090836dc93","claim":"Electromed, Inc. reported Q2 FY 2024 results: revenue $13.7 million, net income $1,674,000, EPS $0.19 per diluted share.","evidence_excerpt":"Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2023 (“Q2 FY 2024”). Q2 FY 2024 Financial Highlights ● Net revenue increased 17% to a record $13.7 million in Q2 FY 2024, from $11.7 million in the second quarter of the prior fiscal year. ● Gross margins were 77% of revenue, compared to 74% in the second quarter of the prior fiscal year. ● Operating income was a record $2,263,000 or 16.5% of revenue, compared with $1,274,000 or 10.9% of revenue in the second quarter of the prior fiscal year. ● Net income was a record $1,674,000 for the quarter, or $0.19 per diluted share, compared to $977,000, or $0.11 per diluted share in the second quarter of the prior fiscal year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488917/000089710124000069/0000897101-24-000069-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q2 FY 2024"},{"label":"Revenue","value":"$13.7 million"},{"label":"Net income","value":"$1,674,000"},{"label":"EPS","value":"$0.19 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}